bpc 157 clinical trials human evidence safety BPC-157 – No Proof Required! | Office for Science and Society bpc-157 human clinical trials evidence
Description
The meeting concerns compounding eligibility only
Since chronic neuroinflammation is a driving force in diabetic neuropathy, chemotherapy-induced neuropathy, and many other forms, this anti-inflammatory mechanism addresses a root cause rather than a downstream symptom
Section 503A of the FDCA allows compounding without FDA premarket approval or full compliance with labeling and current good manufacturing practices, provided specific conditions are met
Imaging 7 , 880886 (1997)
Summary of Key Points: Chemical Identity: Trazodone HCl (CAS 25332-39-2) a SARI-class antidepressant
